7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prescription opioid dispensing in Canada: an update on recent developments to 2018

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Canada has been home to comparatively extreme developments in prescription opioid (PO) availability and related harms (e.g. morbidity, mortality) post-2000. Following persistent pan-Canadian increases in PO use, select control measures were implemented and PO dispensing levels—while only inconsistently by province—inverted, and began to plateau or decrease post-2012. We examined annual PO dispensing levels in Canada up until 2018, based on representative prescription sample data from community-based retail pharmacies. Annual prescription-based dispensing data were converted into defined daily doses/1000 population/day by province, and mainly categorized into ‘weak’ and ‘strong’ opioids. All provinces indicated decreasing trends in strong PO levels in most recent years, yet with inter-provincial differences of up to one magnitude in 2018; in about half the provinces, dispensing fell to below-2005 levels. British Columbia had the largest decline in strong PO dispensing from its peak rate (− 48.5%) in 2011. Weak opioid dispensing trends remained more inconsistent and bifurcated across Canada. The distinct effects of individual—including many provincially initiated and governed—PO control measures urgently need to be evaluated. In the meantime, recent reductions in general PO availability across Canada appear to have contributed to shortages in opioid supply for existent, sizable (including non-medical) user populations and may have contributed to recent marked increases in illicit opioid use and harms (including rising deaths).

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

          Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction

            Annual Review of Public Health, 36(1), 559-574
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century.

              This paper documents a marked increase in the all-cause mortality of middle-aged white non-Hispanic men and women in the United States between 1999 and 2013. This change reversed decades of progress in mortality and was unique to the United States; no other rich country saw a similar turnaround. The midlife mortality reversal was confined to white non-Hispanics; black non-Hispanics and Hispanics at midlife, and those aged 65 and above in every racial and ethnic group, continued to see mortality rates fall. This increase for whites was largely accounted for by increasing death rates from drug and alcohol poisonings, suicide, and chronic liver diseases and cirrhosis. Although all education groups saw increases in mortality from suicide and poisonings, and an overall increase in external cause mortality, those with less education saw the most marked increases. Rising midlife mortality rates of white non-Hispanics were paralleled by increases in midlife morbidity. Self-reported declines in health, mental health, and ability to conduct activities of daily living, and increases in chronic pain and inability to work, as well as clinically measured deteriorations in liver function, all point to growing distress in this population. We comment on potential economic causes and consequences of this deterioration.
                Bookmark

                Author and article information

                Contributors
                bfischer@sfu.ca
                Journal
                J Pharm Policy Pract
                J Pharm Policy Pract
                Journal of Pharmaceutical Policy and Practice
                BioMed Central (London )
                2052-3211
                23 October 2020
                23 October 2020
                2020
                : 13
                : 68
                Affiliations
                [1 ]GRID grid.61971.38, ISNI 0000 0004 1936 7494, Centre for Applied Research in Mental Health and Addiction (CARMHA), Faculty of Health Sciences, , Simon Fraser University, ; Vancouver, Canada
                [2 ]GRID grid.155956.b, ISNI 0000 0000 8793 5925, Centre for Addiction and Mental Health, ; 33 Russell Street, Toronto, Ontario Canada
                [3 ]GRID grid.17063.33, ISNI 0000 0001 2157 2938, Department of Psychiatry, , University of Toronto, ; 250 College Street, 8th floor, Toronto, Ontario Canada
                [4 ]GRID grid.418647.8, ISNI 0000 0000 8849 1617, Institute for Clinical Evaluative Sciences (ICES), ; 2075 Bayview Ave, Toronto, Ontario Canada
                [5 ]GRID grid.9654.e, ISNI 0000 0004 0372 3343, Schools of Population Health and Pharmacy, Faculty of Medical and Health Sciences, , University of Auckland, ; Auckland, New Zealand
                [6 ]GRID grid.411249.b, ISNI 0000 0001 0514 7202, Department of Psychiatry, , Federal University of São Paulo (UNIFESP), ; R. Sena Madureira, 1500 - Vila Clementino, São Paulo, Brazil
                Author information
                http://orcid.org/0000-0002-2186-4030
                Article
                271
                10.1186/s40545-020-00271-x
                7583232
                33110608
                e4fbb3b9-b12a-4ca3-b9d8-4df917246455
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 17 December 2019
                : 4 September 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: SAF94814
                Award Recipient :
                Categories
                Short Report
                Custom metadata
                © The Author(s) 2020

                canada,dispensing,interventions,opioids,public health
                canada, dispensing, interventions, opioids, public health

                Comments

                Comment on this article